Gefitinib Treatment for Pulmonary Sarcomatoid Carcinoma Driven by an EGFR Mutation: Two Cases |
Kim, Ji-Yeon
(Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine)
Lim, Yoojoo (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) Lee, Eunyoung (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) Kim, Mi So (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) Lee, Dae-Won (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) Kim, Tae Min (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) Lee, Se-Hoon (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) |
1 | Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73. DOI ScienceOn |
2 | Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3: 75ra26. |
3 | Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068. DOI ScienceOn |
4 | Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2010;18:103-120. DOI ScienceOn |
5 | Ushiki A, Koizumi T, Kobayashi N, et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol 2009;39:267-270. DOI ScienceOn |
6 | Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388. DOI ScienceOn |
7 | Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500. DOI ScienceOn |
8 | Kaira K, Horie Y, Ayabe E, et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010;5:460-465. DOI ScienceOn |
9 | Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 2009;125:2479-2482. DOI ScienceOn |
10 | Lee S, Kim Y, Sun JM, et al. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 2011;137:1203-1211. DOI |